【摘要】 目的:本研究旨在探讨125I-EGF-BSA靶向纳米载体在荷人乳腺癌SK-BR3裸鼠体内的分布。方法:采用超声乳化-化学交联方法制备牛血清白蛋白纳米载体,经过羧和反应将与白蛋白纳米载体表面的活性氨基与EGF进行偶联反应,制备EGF偶联白蛋白纳米载体。在裸鼠体内进行荷人乳腺癌实验,将荷瘤裸鼠随机分为3个实验组,125I-BSA非纳米载体组(直接在BSA上标记125I),125I-EGF-BSA靶向纳米载体组和125I-BSA纳米载体组,检测不同时间点各组织的放射分布。结果:125I-EGF-BSA靶向纳米载体的瘤/血比值和瘤/肌肉比值明显高于其它两个给药组,差异有统计学意义(P<0.05)。125I-EGF-BSA靶向纳米载体在荷瘤裸鼠体内的放射性瘤/血比值和瘤/肌肉比值随时间逐渐升高,在2h达峰值,后略有下降。做方差分析,同一时间点125I-EGF-BSA靶向纳米载体的放射性瘤/血比值和瘤/肌肉比值均高于其他两个给药组,差异均具有统计学意义(P<0.05)。25I-EGF-BSA靶向纳米载体在肝、脾、肺等器官分布明显低于其它两组,差异有统计学意义(P<0.05)。结论:125I-EGF-BSA靶向纳米载体对裸鼠体内的人乳腺癌SK-BR3肿瘤具有明显的靶向性,而肝、脾、肺等器官的分布少。更多还原

【Abstract】 Objective: To explore the distribution of 125I-EGF-targeting nano-carrier BSA in nude mice bearing SK-BR3 human breast cancer. Methods: We used ultrasound emulsification-chemical cross-linking to prepare bovine serum albumin nanoparticles. Through a carboxymethyl reaction, the active amine group on the surface of albumin nanoparticles was coupled with EGF, forming EGF-conjugated albumin nanoparticles.Nude mice were used to establish the human breast cancer model and were randomly divided into three experimental groups: 125I-BSA non-nano-carrier group(125I directly linked to BSA), 125I-EGF-BSA targeting nano-carrier group, and 125I-BSA nano-carrier group. The radioactive distribution of the particles in different tissues was detected and calculated. Results: The tumor/blood ratio and tumor/muscle ratio in the 125I-EGF-BSA targeting nano-carrier group were higher than those in the other two groups(P<0.05). The distribution of 125I-EGF-BSA targeting nano-carrier in the liver, spleen, lungs and other organs was significantly lower than that in the other two groups(P<0.05). Conclusion: 125I-EGF-BSA targeting nano-carrier has obvious tumor-targeting effects on human breast cancer SK-BR3 in nude mice and is distributed to the liver, spleen, lungs and other organs less effectively.更多还原